Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.67 |
| ▸ | TNF | P01375 | 3/20 | 0.67 |
| ▸ | ACHE | P22303 | 2/20 | 0.67 |
| ▸ | PDE4A | P27815 | 2/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.64 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11754530 | 0.91 | ADORA2B (0.69) | ADORA2BTNFACHEPDE4APDE4B | |
| Bisdionin C SCHEMBL10018600 | 0.91 | CHIT1 (0.75) | ADORA2BTNFACHEPDE4APDE4B | |
| Bisdionin D SCHEMBL16120988 | 0.91 | ADORA2B (0.79) | ADORA2BTNFACHEPDE4APDE4B | |
| SCHEMBL16120981 | 0.89 | ADORA2B (0.77) | ADORA2BTNFACHEPDE4APDE4B | |
| Bisdionin B SCHEMBL29896692 | 0.88 | ADORA2B (0.74) | ADORA2BTNFACHEPDE4APDE4B | |
| SCHEMBL516018 | 0.87 | PDE4A (0.78) | ADORA2BTNFACHEPDE4APDE4B | |
| SCHEMBL3523033 | 0.87 | ADORA2B (0.69) | ADORA2BTNFACHEPDE4APDE4B | |
| SCHEMBL7384278 | 0.86 | ADORA2B (0.68) | ADORA2BTNFACHEPDE4APDE4B | |
| SCHEMBL9293614 | 0.85 | ADORA2B (0.71) | ADORA2BTNFACHEPDE4APDE4B | |
| SCHEMBL11300380 | 0.85 | ADORA2B (0.71) | ADORA2BTNFACHEPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56040685-A | — | — | None | — | — | JP | disclosed |
| JP-55028902-A | — | — | None | — | — | JP | disclosed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| EP-3299371-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016184312-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | 南京明德新药研发股份有限公司 | 2016-11-24 | — | — | WO | disclosed |
| JP-S5640685-A | PREPARATION OF THEOBROMINE DERIVATIVE | MARUKO SEIYAKU KK | 1981-04-16 | — | — | JP | disclosed |
| JP-S5528902-A | PREPARATION OF XANTHINE DERIVATIVE | GRELAN PHARMACEUT CO LTD | 1980-02-29 | — | — | JP | disclosed |
| US-4060618-A | Quaternary xanthinylalkyl nortropine | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140607-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | ADORA2B 89/4885TNF 103/4885ACHE 872/4885 |
| US-10278973-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | ADORA2B 89/4885TNF 103/4885ACHE 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.